Treatment choices, preferences and decision‐making by patients with rheumatoid arthritis
Authors:
- Frances ChiltonFCFrances Chilton
- Raymond A. CollettRCRaymond A. Collett
Open Access
- 28 August 2007
- journal article
- research article
- Published by Wiley in Musculoskeletal Care
- Vol. 6 (1) , 1-14
Abstract
Objectives: To explore rheumatoid arthritis (RA) patient treatment preferences, their decision‐making and the treatment choices they would make when faced with three anti‐tumour necrosis factor‐α (TNF‐α) therapy options.Methods: Two methods of enquiry were used: postal questionnaire and one‐to‐one interviews. RA patients not taking anti‐TNF‐α medications were asked to complete a questionnaire after reading a written scenario, which involved choosing and identifying factors that influenced their treatment choice from three anti‐TNF‐α therapies: etanercept (Enbrel), adalimumab (Humira) and infliximab (Remicade). Patients who had tried more than one anti‐TNF‐α medication were asked at one‐to‐one interviews for their treatment preferences and how their current treatment had been decided.Results: Both interviewees and questionnaire respondents chose adalimumab as their preferred treatment. Interviewees identified lack of control, convenience and technical issues as influencing treatment choice. Questionnaire respondents were less likely than interviewees to want to participate in making decisions about the selection of anti‐TNF‐α therapy. There were few gender differences. Patients younger than 61 years old were more confident about self‐administering treatment, and preferred subcutaneous (sc) over intravenous (iv) medication, as this reduced regular hospital attendance. Older patients preferred health care staff to administer treatment and more readily identified ‘contact with other patients/meeting others’ and ‘staff availability if problems arise’ as factors influencing choice.Conclusions: RA patients demonstrate a clear treatment preference. Different factors influence patients who choose sc compared with iv medications. Many RA patients either wished to share in treatment decisions or relinquish responsibility to the health professional when choosing anti‐TNF‐α therapy. Patients require reassurance and continuing dialogue with clinicians to manage their condition optimally. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 10 references indexed in Scilit:
- Biologic therapies in autoimmune diseasesClinical Medicine, 2006
- Need for information and for involvement in decision making among patients with rheumatoid arthritis: A questionnaire surveyArthritis Care & Research, 2005
- Patients' preferences for involvement in clinical decision-making within secondary care and the factors that influence their preferencesJournal of Nursing Management, 2005
- Does route of administration affect the outcome of TNF antagonist therapy?Arthritis Research & Therapy, 2004
- Designing A Mixed Methods Study In Primary CareThe Annals of Family Medicine, 2004
- The importance of patient preferences in treatment decisions—challenges for doctorsBMJ, 2003
- Variability in patient preferences for participating in medical decision making: implication for the use of decision support toolsQuality and Safety in Health Care, 2001
- What do we mean by partnership in making decisions about treatment?BMJ, 1999
- Sharing decisions with patients: is the information good enough?BMJ, 1999
- What Role Do Patients Wish to Play in Treatment Decision Making?Archives of internal medicine (1960), 1996